JP2010540570A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540570A5
JP2010540570A5 JP2010527303A JP2010527303A JP2010540570A5 JP 2010540570 A5 JP2010540570 A5 JP 2010540570A5 JP 2010527303 A JP2010527303 A JP 2010527303A JP 2010527303 A JP2010527303 A JP 2010527303A JP 2010540570 A5 JP2010540570 A5 JP 2010540570A5
Authority
JP
Japan
Prior art keywords
composition
antigen
composition according
amphiphilic compound
hydrophobic carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010527303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540570A (ja
JP5591705B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/001747 external-priority patent/WO2009043165A1/en
Publication of JP2010540570A publication Critical patent/JP2010540570A/ja
Publication of JP2010540570A5 publication Critical patent/JP2010540570A5/ja
Application granted granted Critical
Publication of JP5591705B2 publication Critical patent/JP5591705B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010527303A 2007-10-03 2008-10-02 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用 Expired - Fee Related JP5591705B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97719707P 2007-10-03 2007-10-03
US60/977,197 2007-10-03
PCT/CA2008/001747 WO2009043165A1 (en) 2007-10-03 2008-10-02 Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof

Publications (3)

Publication Number Publication Date
JP2010540570A JP2010540570A (ja) 2010-12-24
JP2010540570A5 true JP2010540570A5 (cg-RX-API-DMAC7.html) 2011-11-10
JP5591705B2 JP5591705B2 (ja) 2014-09-17

Family

ID=40525804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527303A Expired - Fee Related JP5591705B2 (ja) 2007-10-03 2008-10-02 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用

Country Status (7)

Country Link
EP (1) EP2195022A4 (cg-RX-API-DMAC7.html)
JP (1) JP5591705B2 (cg-RX-API-DMAC7.html)
CN (1) CN101815529B (cg-RX-API-DMAC7.html)
AU (1) AU2008307042B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0817484B1 (cg-RX-API-DMAC7.html)
CA (1) CA2700828C (cg-RX-API-DMAC7.html)
WO (1) WO2009043165A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
WO2009146523A1 (en) 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
IN2014CN02581A (cg-RX-API-DMAC7.html) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
WO2014153636A1 (en) 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. リピドa模倣体、調製方法、及びその使用
CN105044328A (zh) * 2015-05-28 2015-11-11 首都医科大学附属北京佑安医院 Elispot预包被培养板及其制备方法
JP6989134B2 (ja) * 2015-11-18 2022-01-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
CA3022924A1 (en) * 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
CA3038155A1 (en) 2016-09-27 2018-04-05 Immunovaccine Technologies Inc. Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
IL302880A (en) 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based ingredients, production methods, and their uses for inducing an immune response
EP3768242A4 (en) * 2018-03-20 2021-12-08 ImmunoVaccine Technologies Inc. METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES
EP4294431A4 (en) * 2021-02-16 2025-05-07 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles based on amphiphilic peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI944052A7 (fi) * 1992-03-03 1994-09-02 Daiichi Seiyaku Co Oraalinen rokote
US5736141A (en) * 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
AU8053898A (en) * 1997-05-28 1998-12-30 Jenner Biotherapies, Inc. Immunogenic compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP4164361B2 (ja) * 2000-11-07 2008-10-15 イムノワクチン テクノロジーズ インコーポレーテッド 増強した免疫応答を有するワクチン、およびその調製方法
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy

Similar Documents

Publication Publication Date Title
JP2010540570A5 (cg-RX-API-DMAC7.html)
Shi et al. Immunoprotection against influenza virus H9N2 by the oral administration of recombinant Lactobacillus plantarumNC8 expressing hemagglutinin in BALB/c mice
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
Abbaraju et al. Asymmetric mesoporous silica nanoparticles as potent and safe immunoadjuvants provoke high immune responses
Gregg et al. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model
RU2009144125A (ru) Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе
JP2010500398A5 (cg-RX-API-DMAC7.html)
JP2009520712A5 (cg-RX-API-DMAC7.html)
SG10201903538YA (en) Modified virus-like particles of cmv
JP2014502156A5 (cg-RX-API-DMAC7.html)
EA200900024A1 (ru) Противогриппозная вакцина
EA201300101A1 (ru) Лиофилизированная антигенная композиция
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
JP2017501172A5 (cg-RX-API-DMAC7.html)
Li et al. Co-stimulation with TLR7 agonist imiquimod and inactivated influenza virus particles promotes mouse B cell activation, differentiation, and accelerated antigen specific antibody production
RU2017124240A (ru) СПОСОБ ПОЛУЧЕНИЯ ГОТОВОЙ К ПРИМЕНЕНИЮ КОМБИНИРОВАННОЙ ВАКЦИНЫ ПРОТИВ PCV2/M.hyo
RU2017101091A (ru) Композиции вакцин с двойным адъювантом, получение и применения
CN106075419B (zh) 一种杀鲑气单胞菌灭活疫苗及其应用
JP2020533354A5 (cg-RX-API-DMAC7.html)
Emerson et al. Extracellular vesicles elicit protective immune responses against Salmonella infection
Chen et al. Peptide-based therapeutic HPV cancer vaccine synthesized via bacterial outer membrane vesicles
Singh et al. Glycan-based shaping of the microbiota during primate evolution
PH12013500036A1 (en) Vaccine compositions based on sticholysin encapsulated into liposomes
Katare et al. Development of polysaccharide-capped niosomes for oral immunization of tetanus toxoid
JP2013528211A5 (cg-RX-API-DMAC7.html)